JunAP / Sapience Therap - LARVOL DELTA

JunAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in TNBC models (AACR 2024) - "Further, in a BT549 triple negative breast cancer subcutaneous xenograft model, administration of JunAP results in tumor regression, demonstrating the anti-cancer potential of targeting the AP-1 complex. In summary, these data support JunAP as a potent peptide antagonist of the AP-1 transcription factor family that warrants further development as a potential therapeutic option for AP-1 driven tumors."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PRNewswire) - "Abstract Number: 3051:...AP-1 complexes consisting of c-Jun and Fra1 are implicated in the survival of a diverse set of tumors. JunAP targets and blocks c-Jun and Fra1 dimerization, inhibits AP-1 transcriptional activity and inhibits AP-1-dependent cell survival and invasion in vitro. JunAP demonstrates potent anti-tumor activity in vivo in mouse triple negative breast cancer and melanoma tumor models."

Preclinical • Melanoma • Triple Negative Breast Cancer

Sapience Therapeutics to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PRNewswire) - "Sapience Therapeutics...announced three poster presentations at the 2024 American Association for Cancer Research (AACR)....Sapience will present non-clinical immunotherapy results at AACR from both of its clinical programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ. Sapience will also present first disclosure of pre-clinical data describing its first-in-class AP-1 complex antagonist targeting the interaction of cJun with Fra1."

Preclinical • Triple Negative Breast Cancer